Finance

Lists
1177:HKG
Sino Biopharmaceutical Ltd
HK$5,25
-0,38%
(-0,020) 1D
16 Okt., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1177...
Open
HK$5,40
High
HK$5,50
Low
HK$5,14
Mkt. cap
98,09 mjd
Avg. vol.
69,33 m
Volume
83,88 m
Dividend
2,29%
Quarterly dividend
HK$0,03
Ex-dividend date
29 Aug. 2025
P/E ratio
33,86
52-wk high
HK$7,79
52-wk low
HK$4,19
EPS
HK$0,16
Shares outstanding
12,64 mjd
No. of employees
23 k
Open
HK$5,40
High
HK$5,50
Low
HK$5,14
Mkt. cap
98,09 mjd
Avg. vol.
69,33 m
Volume
83,88 m
Dividend
2,29%
Quarterly dividend
HK$0,03
Ex-dividend date
29 Aug. 2025
P/E ratio
33,86
52-wk high
HK$7,79
52-wk low
HK$4,19
EPS
HK$0,16
Shares outstanding
12,64 mjd
No. of employees
23 k
News stories
From web sources and news partners
Profile
Sino Biopharmaceutical Limited, shortly SBP Group, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
About Sino Biopharmaceutical Ltd
CEOLi Yi
Employees22,8 k
Founded2000
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
7,13 mjd
7,13 mjd
9,72 mjd
9,72 mjd
Cost of goods sold
1,31 mjd
1,31 mjd
1,65 mjd
1,65 mjd
Cost of revenue
1,31 mjd
1,31 mjd
1,65 mjd
1,65 mjd
Research and development expenses
2,93 mjd
2,93 mjd
1,54 mjd
1,54 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,80 mjd
2,80 mjd
3,11 mjd
3,11 mjd
Operating expense
4,38 mjd
4,38 mjd
4,77 mjd
4,77 mjd
Total operating expenses
5,69 mjd
5,69 mjd
6,42 mjd
6,42 mjd
Operating income
1,44 mjd
1,44 mjd
3,31 mjd
3,31 mjd
Other non operating income
97,99 m
97,99 m
76,64 m
76,64 m
EBT including unusual items
488,22 m
488,22 m
3,67 mjd
3,67 mjd
EBT excluding unusual items
1,55 mjd
1,55 mjd
3,56 mjd
3,56 mjd
Income tax expense
323,77 m
323,77 m
597,96 m
597,96 m
Effective tax rate
66,32%
66,32%
16,29%
16,29%
Other operating expenses
-1,35 mjd
-1,35 mjd
113,21 m
113,21 m
Net income
-522,62 m
-522,62 m
1,72 mjd
1,72 mjd
Net profit margin
-7,33%
-7,33%
17,66%
17,66%
Earnings per share
-
-
-
-
Interest and investment income
196,36 m
196,36 m
250,06 m
250,06 m
Interest expense
-77,56 m
-77,56 m
-84,75 m
-84,75 m
Net interest expenses
118,80 m
118,80 m
165,31 m
165,31 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,66 mjd
1,66 mjd
3,57 mjd
3,57 mjd
Gain or loss from assets sale
-5,58 m
-5,58 m
-
-
AI content may include mistakes. Learn more
Google-programme